Statin and SGLT2i: Statin as atrovastatin SGLT2i as dapagliflozin
Study summary
correlate the serum level of statin and SGLT2i when given as polytherapy with HPLC in ischemic heart failure patients and their laboratory tests (cholesterol, LDL, HDL and TG...)
Eligibility
Sex
ALL
Min age
50 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* we include patients established ischemic heart failure seen by a primary care provider to diagnose ischemic heart disease,
* They assessed the use of statin with SGLT2i.
Exclusion Criteria:
* We exclude patients with
1. liver dysfunction.
2. renal dysfunction.
3. fungal infection.
4. coagulation disorder.
5. Pts using drugs that interact with SGLT2i.
6. patients that will refuse to be enrolled in the Study or refuse to write informed consent.
Primary outcome measure(s)
The Effect of The combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart disease — Three months of follow up correlate the serum level of statin and SGLT2i when given as polytherapy with ECG in ischemic heart failure patients and their laboratory tests (cholesterol, LDL, HDL and TG...)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.